
    
      OBJECTIVES: I. Determine whether aspirin administered at a dose of 325 mg/day will decrease
      the number and size of new adenomas in patients with Dukes' A/B1/B2/C colorectal cancer who
      have undergone curative surgical resection. II. Assess whether this dose of aspirin will
      increase disease-free survival in these patients.

      OUTLINE: Randomized, double-blind study. Arm I: Chemoprevention. Enteric-coated Aspirin, ASA,
      NSC-27223. Arm II: Control. Placebo, PLCB.
    
  